Atlas Trials

Refractory Histiocytic and Dendritic Cell Neoplasm

3 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Histiocytic and Dendritic Cell Neoplasm

RecordFirmDate
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888)National Cancer Institute (NCI)2021-05-03
Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma (NCT04640779)Mayo Clinic2021-02-08
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994)National Cancer Institute (NCI)2018-11-14

Track Refractory Histiocytic and Dendritic Cell Neoplasm automatically

Every clearance here is in the API, with alerts when new ones post.